Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2004 3
2005 1
2006 2
2007 2
2008 2
2009 4
2010 1
2011 2
2012 1
2013 2
2014 1
2015 1
2016 1
2017 2
2018 4
2019 3
2020 4
2021 7
2022 5
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: Books and Documents, Clinical Trial, Meta-Analysis, Randomized Controlled Trial, Review, Systematic Review. Clear all
Page 1
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Gomez-Veiga F, Szmulewitz RZ, Holzbeierlein J, Azad AA, Iguchi T, Villers A, Alcaraz A, Alekseev B, Shore ND, Rosbrook B, Zohren F, Ma J, Haas GP, Stenzl A, Armstrong AJ. Gomez-Veiga F, et al. Among authors: holzbeierlein j. Eur Urol Oncol. 2024 Aug;7(4):860-869. doi: 10.1016/j.euo.2023.11.012. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072761 Free article. Clinical Trial.
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, Szmulewitz RZ, Alcaraz A, Shore ND, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas GP, Gourgiotti G, El-Chaar N, Stenzl A. Armstrong AJ, et al. Among authors: holzbeierlein j. Eur Urol. 2023 Aug;84(2):229-241. doi: 10.1016/j.eururo.2023.04.002. Epub 2023 May 12. Eur Urol. 2023. PMID: 37179240 Free article. Clinical Trial.
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Stenzl A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Ivanescu C, Rosbrook B, Ramaswamy K, Ganguli A, Haas GP, Armstrong AJ. Stenzl A, et al. Among authors: holzbeierlein j. Prostate. 2022 Sep;82(13):1237-1247. doi: 10.1002/pros.24396. Epub 2022 Jun 8. Prostate. 2022. PMID: 35675470 Clinical Trial.
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Armstrong AJ, et al. Among authors: holzbeierlein j. J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14. J Clin Oncol. 2022. PMID: 35420921 Free PMC article. Clinical Trial.
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Azad AA, et al. Among authors: holzbeierlein j. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):274-282. doi: 10.1038/s41391-021-00436-y. Epub 2021 Aug 21. Prostate Cancer Prostatic Dis. 2022. PMID: 34420037 Clinical Trial.
Intensive preoperative ostomy education for the radical cystectomy patient.
Zganjar A, Glavin K, Mann K, Dahlgren A, Thompson J, Wulff-Burchfield E, Winright S, Heim A, Wyre H, Lee E, Taylor J, Holzbeierlein J, Mirza M. Zganjar A, et al. Among authors: holzbeierlein j. Urol Oncol. 2022 Nov;40(11):481-486. doi: 10.1016/j.urolonc.2021.04.025. Epub 2021 Jun 16. Urol Oncol. 2022. PMID: 34140243 Review.
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. Denmeade SR, et al. Among authors: holzbeierlein jm. J Clin Oncol. 2021 Apr 20;39(12):1371-1382. doi: 10.1200/JCO.20.02759. Epub 2021 Feb 22. J Clin Oncol. 2021. PMID: 33617303 Free PMC article. Clinical Trial.
43 results